Wavy Abstract Background

Overview of COVID-19 Lung Damage Clinical Trial

June 16th, 2020


SDARTs faculty member, Robert W. Alexander, MD, DDS, is the Principle Investigator on a first-in-human clinical trial to treat post-COVID 19 survivors with AD cSVF.


Many moderate to severe post-COVID 19 survivors experience compromised lung function. As a proposed solution, adipose-derived cellular stromal vascular fraction (AD cSVF) may be effective in reversing residual damage to the lungs and gas exchange functions.


This article was published in Stem Cell Research.

Overview_COVID-19_Lung_Damage_cSVF_Final_6-10-20_Stem_Cell_Res
.pdf
Download PDF • 500KB
 

Want to learn more from Dr. Alexander?

Visit the SDARTs Online Learning Center >

Recent Posts

See All